Gigabases Switzerland AG
Gigabases is a Swiss company revolutionizing synthetic biology by leveraging AI and advanced 3D protein design technology. Their platform offers a vast database of over 214 million protein 3D structures and enables researchers to design custom proteins at the amino acid level. The platform's algorithms convert these designs into ready-to-order, sequence-verified expression plasmids for mammalian, viral, and bacterial systems, streamlining the research process. Gigabases originated as an ETH spin-off and focuses on big data biology to empower biotechnology and biomedicine innovations. Their product suite includes a variety of plasmids optimized for different expression needs, supporting over 56,000 human proteins and 36.8 million specialty enzymes, with applications in rare genetic diseases. The company operates on a SaaS and product sales model, targeting researchers and biotech companies.
Gigabases Switzerland AG
Gigabases is a Swiss company revolutionizing synthetic biology by leveraging AI and advanced 3D protein design technology. Their platform offers a vast database of over 214 million protein 3D structures and enables researchers to design custom proteins at the amino acid level. The platform's algorithms convert these designs into ready-to-order, sequence-verified expression plasmids for mammalian, viral, and bacterial systems, streamlining the research process. Gigabases originated as an ETH spin-off and focuses on big data biology to empower biotechnology and biomedicine innovations. Their product suite includes a variety of plasmids optimized for different expression needs, supporting over 56,000 human proteins and 36.8 million specialty enzymes, with applications in rare genetic diseases. The company operates on a SaaS and product sales model, targeting researchers and biotech companies.